Evidence map›Paper›PMID 36551585›Full record

ArticleCancers2022

Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study.

Ilaria Pellegrini, Cas Drabbe, Dirk J Grünhagen, Michiel A J Van de Sande, Jacco J de Haan, Kristien B M I Keymeulen, Johannes J Bonenkamp, Winette T A Van der Graaf, Olga Husson

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Ilaria PellegriniDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Cas DrabbeDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Dirk J GrünhagenDepartment of Surgical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-8293-6002
Michiel A J Van de SandeDepartment of Orthopaedic Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-9156-7656
Jacco J de HaanDepartment of Medical Oncology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-1629-4715
Kristien B M I KeymeulenDepartment of Surgical Oncology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
Johannes J BonenkampDepartment of Surgical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Winette T A Van der GraafDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0001-7549-3338
Olga HussonDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0002-1387-8686
The Netherlands Cancer Institute · NLErasmus MC Cancer Institute · NLInstitute of Cancer Research · GBLeiden University Medical Center · NLMaastricht University · NLRadboud University Nijmegen · NLUniversity Medical Center Groningen · NL

Funding

The PROFILES registry was funded by an Investment Grant Medium (#480-08-009) of the Neth-erlands Organization for Scientific Research (The Hague, the Netherlands). The present research was supported by an Investment Grant Large 2016/04981/ZONMW-91101002) (198.007)
6 · The paper itself

Abstract

Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care.

methodsA cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care.

resultsIn total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25;

conclusionsSevere FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.

Indexed as

fear of cancer recurrencefollow-uphealth-related quality of lifesarcomasurvivors

Identifiers

PMID36551585
PMCPMC9776518
OpenAlexW4312127302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.